ESMO: Nivolumab combined with chemotherapy and neoadjuvant therapy reduces the risk of EFS by 43% in patients with resectable non-small cell lung cancer (Checkmate-816 study
Time of Update: 2022-04-23
The results showed that compared with chemotherapy alone, patients with stage Ib-IIIa resectable non-small cell lung cancer (NSCLC) who received 3 cycles of nivolumab combined with chemotherapy before surgery could significantly improve the tumor pathological complete response ( pCR), meeting the primary study endpoint .
J INTERN MED: The relationship between apolipoprotein A-IV concentration and clinical outcome in patients with chronic kidney disease
Time of Update: 2022-01-07
Researchers aimed to investigate the association between apoA-IV levels and all-cause mortality and cardiovascular outcomes in the German Chronic Kidney Disease (GCKD) study .
In a large chronic kidney disease patient, ApoA-IV levels appear to be an independent risk marker for reducing all-cause mortality, cardiovascular events, and heart failure .
JCEM: EMR-based mixed diagnosis model improves the diagnosis of familial hypercholesterolemia
Time of Update: 2022-01-07
In order to standardize the collection of family history data, graduate students from the local pharmacy school and other graduate students received training to collect high-risk patients (DLCNS=5 or low-density lipoprotein cholesterol ≥ 190 mg/dL) of early-onset cardiovascular disease or Family history of cerebrovascular accident .
Lancet Oncol: Maintenance therapy with daratumumab can significantly reduce the risk of disease progression and death in patients with multiple myeloma
Time of Update: 2021-09-29
The results of Part 1 of the CASSIOPEIA study showed that newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation (ASCT) were treated with daretuzumab, bortezomib, thalidomide, and dexamethasone (D- The depth of remission and progression-free survival of the VTd) regimen as an induction and consolidation treatment were significantly better than those of bortezomib, thalidomide, and dexamethasone (VTd) regimens .
Compu Biopharmaceuticals launched the KPG-818 Treatment SLE Ib/IIa Phase Clinical Trial in the United States
Time of Update: 2021-01-21
addition, Compu Biopharmaceuticals has recently received FDA approval for a phase IIa clinical trial of KPG-818 for the treatment of new coronavirus pneumonia in the United States.
Nice's decision on erlotinib depends on its cost comparison with gefitinib
Time of Update: 2012-02-21
Source: Elsevier 2012-02-21 the cost benefit management agency in England and Wales issued a new draft of guidance, pointing out that erlotinib cannot be recommended as the first-line treatment for ad